BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

940 related articles for article (PubMed ID: 23610105)

  • 1. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
    Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O
    J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
    Mazières J; Barlesi F; Filleron T; Besse B; Monnet I; Beau-Faller M; Peters S; Dansin E; Früh M; Pless M; Rosell R; Wislez M; Fournel P; Westeel V; Cappuzzo F; Cortot A; Moro-Sibilot D; Milia J; Gautschi O
    Ann Oncol; 2016 Feb; 27(2):281-6. PubMed ID: 26598547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.
    Eng J; Hsu M; Chaft JE; Kris MG; Arcila ME; Li BT
    Lung Cancer; 2016 Sep; 99():53-6. PubMed ID: 27565914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.
    Lee K; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Res Treat; 2020 Jan; 52(1):292-300. PubMed ID: 31345011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
    Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
    Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
    Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
    Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
    Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y
    Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring
    Mazieres J; Lafitte C; Ricordel C; Greillier L; Negre E; Zalcman G; Domblides C; Madelaine J; Bennouna J; Mascaux C; Moro-Sibilot D; Pinquie F; Cortot AB; Otto J; Cadranel J; Langlais A; Morin F; Westeel V; Besse B
    J Clin Oncol; 2022 Mar; 40(7):719-728. PubMed ID: 35073148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol.
    Ohashi K; Hotta K; Hirata T; Aoe K; Kozuki T; Ninomiya K; Kayatani H; Yanai H; Toyooka S; Hinotsu S; Takata M; Kiura K
    Clin Lung Cancer; 2017 Jan; 18(1):92-95. PubMed ID: 27497829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
    Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
    Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
    Choi MK; Hong JY; Chang WJ; Kim MJ; Kim SM; Jung HA; Do IG; Choi YL; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1229-36. PubMed ID: 25903122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.
    Oh IJ; Hur JY; Park CK; Kim YC; Kim SJ; Lee MK; Kim HJ; Lee KY; Lee JC; Choi CM
    Clin Lung Cancer; 2018 Sep; 19(5):e775-e781. PubMed ID: 30149884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
    Ou SI; Schrock AB; Bocharov EV; Klempner SJ; Haddad CK; Steinecker G; Johnson M; Gitlitz BJ; Chung J; Campregher PV; Ross JS; Stephens PJ; Miller VA; Suh JH; Ali SM; Velcheti V
    J Thorac Oncol; 2017 Mar; 12(3):446-457. PubMed ID: 27903463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.
    Lai WV; Lebas L; Barnes TA; Milia J; Ni A; Gautschi O; Peters S; Ferrara R; Plodkowski AJ; Kavanagh J; Sabari JK; Clarke SJ; Pavlakis N; Drilon A; Rudin CM; Arcila ME; Leighl NB; Shepherd FA; Kris MG; Mazières J; Li BT
    Eur J Cancer; 2019 Mar; 109():28-35. PubMed ID: 30685684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
    Prelaj A; Bottiglieri A; Proto C; Lo Russo G; Signorelli D; Ferrara R; Galli G; De Toma A; Viscardi G; Brambilla M; Lobefaro R; Nichetti F; Manglaviti S; Occhipinti M; Labianca A; Ganzinelli M; Gallucci R; Zilembo N; Greco GF; Torri V; de Braud F; Garassino MC
    Eur J Cancer; 2021 May; 149():235-248. PubMed ID: 33820681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
    Zappa F; Droege C; Betticher D; von Moos R; Bubendorf L; Ochsenbein A; Gautschi O; Oppliger Leibundgut E; Froesch P; Stahel R; Hess T; Rauch D; Schmid P; Mayer M; Crowe S; Brauchli P; Ribi K; Pless M;
    Lung Cancer; 2012 Dec; 78(3):239-44. PubMed ID: 23009726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
    Ross HJ; Blumenschein GR; Aisner J; Damjanov N; Dowlati A; Garst J; Rigas JR; Smylie M; Hassani H; Allen KE; Leopold L; Zaks TZ; Shepherd FA
    Clin Cancer Res; 2010 Mar; 16(6):1938-49. PubMed ID: 20215545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
    Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
    Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.